Lucas Blanchard

Postdoc in Jeffrey Ravetch lab @RockefellerUniv

[Cancer Immunology Research @CIR_AACR]

Targeting Myeloid Cells for Cancer Immunotherapy: https://t.co/i70Uw5wO6w @juanosoriomd @LucasBlch

[Juan C Osorio MD @juanosoriomd]

Our review on myeloid-targeting therapies in cancer immunotherapy is out in @CIR_AACR ! 🔬
We highlight recent advances, key challenges, and opportunities for translating these tx to the clinic.
Huge thx to @LucasBlch for leading this work and Andrew Mijacika!

[Juan C Osorio MD @juanosoriomd]

Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work led to this moment, made possible by an amazing team! 🧵 🪡 https://t.co/Nz3UyjDDuk

[Myriam Chalabi @MyriamChalabi]

Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in @NatureCancer @lab_kok
https://t.co/HbH5Mm2dvn

[Nature Reviews Cancer @NatureRevCancer]

🚨 REVIEW🚨

Vignali & colleagues outline the various contributions of #Tregs to tumour progression & highlight ways in which they represent an attractive #nextgen immunotherapeutic target.

📖 👇
https://t.co/sWEgTVpJxG

[Lucas Blanchard @LucasBlch]

Thank you ACIR for highlighting our recent study ! 🎉

[ACIR @ACIR_org]

Blanchard and Vina et al. investigated mechanisms by which anti-CTLA-4 mAbs modulate tumor-associated high endothelial venules (TA-HEVs), which are important for supporting lymphocyte entry into tumors. https://t.co/TVzD8c9ZgT  @LucasBlch

[Lucas Blanchard @LucasBlch]

We have previously shown that TA-HEVs are critical blood vessels that mediate lymphocyte entry into tumors during cancer immunotherapy, which suggested that strategies increasing TA-HEVs could improve treatment efficacy in non-responsive 'cold' tumors.

https://t.co/ePzxdA5CKK

[CNRS Biologie @CNRSbiologie]

#ResultatScientifique🔎| Un nouvel anticorps pour améliorer l’efficacité de l’immunothérapie

🤝@CNRS @CNRS_Toulouse @Univ_Toulouse
✍️ Jean-Philippe Girard
📕 @CellRepMed | https://t.co/iuGYofcYOh
https://t.co/ZMhzbSY4LE

[Bladder Cancer Advocacy Network @BladderCancerUS]

🚨 PLEASE SHARE! Early-career bladder cancer researchers: Apply now for BCAN's 2025 Young Investigator Awards! $75K in funding, mentorship, and networking opportunities await. Advance your research and career. 🧬 Deadline: Feb 21, 2025. Click for info: https://t.co/xWNQCij621

[AI image]

[Breelyn Wilky, MD 🎗 @breelynwilkyMD]

Very excited to see this in print! Such promising outcomes for immune cold #sarcomas with Botensilimab Plus Balstilimab https://t.co/U679Y5jlJi @Agenus_Bio @CUCancerCenter

[Myriam Chalabi @MyriamChalabi]

Long awaited practice-changing results from ph 3 CM8HW now out in @TheLancet. Nivo/ipi sign better than nivo mono in dMMR mCRC
@sara_lonardi1 @bmsnews #GI25
https://t.co/k3MKGriWPV

[Rony Dahan @DahanLab]

Just published📢 Our new forum article on Fc-optimized checkpoint antibodies for cancer therapy. New to immunotherapy and antibody engineering? This one’s for you! Co-authored with Alan Korman. @TrendsMolecMed #CancerImmunotherapy #FcEngineering

https://t.co/y49YrGDSdr

[Haydn Kissick @HaydnKissick]

Check out our latest paper “Differentiation fate of a stem-like CD4 T cell control immunity to cancer”, led by @Maria_Carden1 now live @Nature https://t.co/CrbGlEdQja . This work examines how CD4 T cell differentiation dictates the outcome of the cancer response. Thread below

[Zach Buchwald MD PhD @zach_buchwald]

Plz check out our new paper on pre-op SRS and the immune microenvironment of human brain metastases. https://t.co/VGCKqH4LAC

Big team effort: @careyjans @meghatron2016 @HaydnKissick @Maria_Carden1 @MohammadKhanMD and many more.

[Matthia Karreman @MA_Karreman]

How do T cells reach melanoma brain tumors?

Using in vivo microscopy, we discovered a new route for T cells to enter the brain via distinct peri-tumoral venous vessels.

Our newest paper is now online @ImmunityCP.
https://t.co/8Ooat6Tlfy

A 🧵👇

[Lucas Blanchard @LucasBlch]

@KevinWNg @BladderCancerUS @RockefellerUniv Thanks Kevin !!

[Lucas Blanchard @LucasBlch]

Grateful and honored that our project on the therapeutic targeting of regulatory T cells (Tregs) was selected by @BladderCancerUS 🙏🏻

Let’s deplete these Tregs !

@RockefellerUniv

[Bladder Cancer Advocacy Network @BladderCancerUS]

Welcome to the cohort, Lucas Blanchard, PhD (@LucasBlch)! Dr. Blanchard has received a BCAN 2024 Young Investigator Award. You can learn more about his research proposal and the award here: https://t.co/Jb6qJyKXMZ

[ACIR @ACIR_org]

To improve agonist CD40 Abs for clinical use, Osorio, Knorr, Weitzenfeld, et al. evaluated 2141-V11, an Fc-engineered anti-CD40 (with optimized FcγRIIB binding) in a phase 1 study (12 patients). https://t.co/isQwOPtqp0  @RockefellerUniv

[Juan C Osorio MD @juanosoriomd]

Pleased to share our recent work on the interplay of obesity and IO responses in endometrial cancer at @jclinicalinves. @ngomezbanoy did a fantastic job leading this work. Thanks to Paul Cohen and the @TeamEndo_MSK supporting this. 3 🇨🇴 here! See 🧵 below! https://t.co/VtsShRJznm

[Agenus @Agenus_Bio]

Results from our Phase 1 clinical trial on the combination of botensilimab and balstilimab for MSS mCRC have been published in @NatureMedicine. Read the full publication here: https://t.co/KN6bDp3eWX